Conference Coverage

Rituximab for RA: Think like a European

Publish date: February 24, 2015

 

EXPERT ANALYSIS FROM THE WINTER RHEUMATOLOGY SYMPOSIUM

References

Dr. Weinblatt reported receiving consulting fees or other remuneration from more than two dozen pharmaceutical companies, including Genentech, which markets rituximab.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Acute RA flares increase risk of cardiovascular disease
MDedge Family Medicine
Smoking impairs biologic response in axial spondyloarthritis
MDedge Family Medicine
IOM report calls for new criteria, new name for chronic fatigue syndrome
MDedge Family Medicine
New concerns rise over iatrogenic hydroxychloroquine retinopathy
MDedge Family Medicine
ACL repair: ‘We have to do better’
MDedge Family Medicine
VIDEO: As biosimilars arrive in U.S., treatment questions arise
MDedge Family Medicine
An expert on primary Raynaud’s phenomenon describes treatment approach
MDedge Family Medicine
How to halt ‘a heart attack of the finger’
MDedge Family Medicine
Differentiating between primary and secondary Raynaud’s
MDedge Family Medicine
VIDEO: Ask patients about metal-on-metal hip implants
MDedge Family Medicine